Darpp-32 and Its Truncated Variant t-Darpp Have Antagonistic Effects on Breast Cancer Cell Growth and Herceptin Resistance

BACKGROUND: Herceptin (trastuzumab) is a humanized monoclonal antibody that is approved for the treatment of metastatic breast cancer patients whose tumors overexpress Her2 (erbB2/neu). Up to 70% of Her2-positive breast cancers demonstrate a response to Herceptin-based therapies, but resistance almo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Long, Waliany, Sarah, Kane, Susan E.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704867/
https://www.ncbi.nlm.nih.gov/pubmed/19593441
http://dx.doi.org/10.1371/journal.pone.0006220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704867/
https://www.ncbi.nlm.nih.gov/pubmed/19593441
http://dx.doi.org/10.1371/journal.pone.0006220

Ejemplares similares